Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions
Clinical and Experimental Dermatology · 24.04.2025 · 50 (5) · 952-959
DOI: 10.1093/ced/llae530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 06.12.2024. Verfasst von Teppei Hagino und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Psoriasis, Nail Diseases, Scalp Dermatoses, Dermatologic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
The long-term (around 1-year) effectiveness and safety of deucravacitinib for the treatment of psoriasis have not been extensively studied in real-world settings, particularly in difficult-to-treat areas, such as the genital, scalp and nail regions.
Objectives
To evaluate the 52-week real-world effectiveness and safety of deucravacitinib in patients with moderate-to-severe psoriasis of the genital, scalp and nail regions.
Methods
This prospective study analysed 104 patients with moderate-to-severe plaque psoriasis treated with deucravacitinib. Clinical scores, Psoriasis Area and Severity Index (PASI), both static and site-specific Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and laboratory inflammatory indices were assessed during a 52-week period.
Results
Deucravacitinib decreased clinical severity scores, and the decrease was sustained for 52 weeks. At week 52, 86% (37/43), 63% (27/43) and 26% (11/43) of patients achieved PASI 75, PASI 90 and PASI 100 reductions (representing a ≥ 75%, ≥ 90% or 100% improvement from baseline), respectively. Deucravacitinib reduced the PGA scores for the genital, scalp and nail regions, as well as the DLQI. Among the patients who completed the 52-week treatment, no significant impact on laboratory inflammatory indices was observed, and no severe or lethal adverse events were reported. Not all patients completed the full 52-week treatment period, as some discontinued early due to adverse events or for other reasons.
Conclusions
Deucravacitinib may be a promising long-term treatment option for psoriasis, demonstrating sustained effectiveness and safety, including in difficult-to-treat areas, such as the genital, scalp and nail regions in real-world clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Fujimoto Dermatology Clinic, Funabashi, Japan.
ORCID-Profile: Teppei Hagino
Zitieren
APA
Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2025). Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions. Clinical and Experimental Dermatology, 50(5), 952-959. https://doi.org/10.1093/ced/llae530
Vancouver
Hagino T, Saeki H, Fujimoto E, Kanda N. Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions. Clinical and Experimental Dermatology. 2025;50(5):952-959. doi:10.1093/ced/llae530
BibTeX
@article{Hagino2025,
author = {Hagino, Teppei and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
title = {Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions},
journal = {Clinical and Experimental Dermatology},
year = {2025},
volume = {50},
number = {5},
pages = {952--959},
doi = {10.1093/ced/llae530}
}
EUVIMED